Grace Therapeutics, Inc. (GRCE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Grace Therapeutics, Inc. (GRCE) closed at USD 1.89 on 2026-10-14, a change of -40.8 % over the past year, with a market capitalization of USD 41.02M.

Grace Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Grace Therapeutics, Inc. key figures

Previous close

USD 1.89 (2026-10-14)

1-year change

-40.8 %

Market cap

USD 41.02M

Enterprise value

USD 27.26M

P/E ratio (trailing)

-1.71

P/E ratio (forward)

-4.33

EPS (trailing)

-1.14

EPS (forward)

-0.45

PEG ratio

n/a

Price to book

0.66

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.82

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Grace Therapeutics, Inc. and compare it with other stocks.